RSA 126-Z:6 · Telehealth Prescreening

Source history

• 2025, 304:5, eff. Jan. 1, 2026

Related materials

Bill relationships

• 2026 HB1292 amend · effective 2027-01-01

  l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati

• 2026 HB1292 amend · effective 2027-01-01

  or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 3 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 2026 HB1292-FN amend · effective 2027-01-01

  or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 3 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 2026 HB1292-FN amend · effective 2027-01-01

  l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati

• 2026 HB1735 amend

  or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 2 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 2026 HB1735-FN amend

  or court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 2 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 2026 HB1809 reference · effective 2030-11-01

  ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat

• 2026 HB1809-FN reference · effective 2030-11-01

  ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat

• 2026 SB504 amend · effective 2027-01-01

  r court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 18 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 2026 SB504 reference · effective 2027-01-01

  nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t

• 2026 SB504-FN amend · effective 2027-01-01

  r court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. 18 Telehealth Prescreening. Amend RSA 126-Z:6, I to read as follows: I. Notwithstanding any regulation or provision of law to the contrary, any health care provider, while physically located in New Hampshire, may conduct a telehealth prescreening with any patie

• 2026 SB504-FN reference · effective 2027-01-01

  nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t